Odyssey Therapeutics Q3 2026 net loss widens 50% to $53.1 million

Bitget2026/11/04 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Odyssey Therapeutics’ third-quarter 2026 net loss widened 50% year over year to $53.1 million.
Research and development expenses jumped 60% to $42.1 million, primarily due to higher external costs for advancing clinical and preclinical programs.
Cash, cash equivalents and marketable securities totaled $387 million at September 30, 2026, expected to fund operations into the second half of 2028.
OD-001 topline induction results from Phase 2b monotherapy and Phase 2a combination trials are expected in the second half of 2027.
Following completed IND-enabling studies, OD-002’s Phase 1/2a trial is expected to begin in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Odyssey Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869605) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Odyssey Therapeutics Q3 2026 net loss widens 50% to $53.1 million

You may also like

Crypto prices